InvestorsHub Logo
Followers 11
Posts 445
Boards Moderated 0
Alias Born 09/23/2018

Re: None

Saturday, 07/27/2019 10:25:59 AM

Saturday, July 27, 2019 10:25:59 AM

Post# of 426292
Hi all. I enjoy reading everyone's posts and invaluable links. Lots of smart folks here. Being a newbie to this board, I don't want to step on any toes, but I would like to see if some here are willing to switch gears a bit and redirect their focus. By this I mean can we all assume Vascepa is the best thing since sliced bread? AMRN knows this, BP knows this, the FDA knows this, and we know this. As such, why would Wall Street still be undervaluing this company? We are left with one variable--competition resulting from weaknesses in patent protection. Let's put ourselves in the shoes of Kennedy. What are the threats and what are the weaknesses directly related to AMRN's patents? We already know the flip side of this SWOT analysis. Why does Kennedy feel obligated to draft a Citizen's Petition? Why hasn't AMRN settled it's current patent litigation? As Whalatane recently posted, "some fear is a good thing". It keeps us honest. We should explore what we fear most.

Long AMRN.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News